DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Depo-Medrol (Methylprednisolone Acetate) - Summary

 
 



DEPO-MEDROL SUMMARY

DEPO-MEDROL is an anti-inflammatory glucocorticoid for intramuscular, intra-articular, soft tissue, or intralesional injection. It is available in three strengths: 20 mg/mL; 40 mg/mL; 80 mg/mL.

When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows:

Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions.

Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).

Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.

Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis.

Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.

Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.

Neoplastic Diseases: For palliative management of leukemias and lymphomas.

Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy.

Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.

Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus.

Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.

Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

 

(See WARNINGS)

DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

 

DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques, necrobiosis lipoidica diabeticorum.
DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).

 


See all Depo-Medrol indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Depo-Medrol (Methylprednisolone)

Double-blind, placebo-controlled pilot randomized trial of methylprednisolone infusion in pediatric acute respiratory distress syndrome. [2015]
syndrome... CONCLUSION: This study demonstrates the feasibility of administering low-dose

Effect of timing and route of methylprednisolone administration during pediatric cardiac surgical procedures. [2015]
cardiopulmonary bypass (CPB) prime... CONCLUSIONS: Methylprednisolone administration at anesthesia induction was

A comparison of the effects of methylprednisolone and tenoxicam on pain, edema, and trismus after impacted lower third molar extraction. [2014]
CONCLUSIONS: Preoperative administration of 80 mg methylprednisolone achieves

Efficiency of bupivacaine versus lidocaine and methylprednisolone versus placebo to reduce postoperative pain and swelling after surgical removal of mandibular third molars: a randomized, double-blinded, crossover clinical trial. [2013]
swelling after surgical removal of mandibular third molars... CONCLUSIONS: Bupivacaine combined with methylprednisolone reduced the

Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome. [2013]
administration varies considerably between different institutions... CONCLUSIONS: Intravenous 30 mg/kg methylprednisolone administered before

more studies >>

Clinical Trials Related to Depo-Medrol (Methylprednisolone)

A Comparison of Three Different Formulations of Prednisolone Acetate 1% [Completed]

Prednisolone Priming Study in Patients With Chronic Hepatitis B [Recruiting]
Study purpose: To investigate whether ALT rebound following corticosteroid priming enhances response to telbivudine therapy. Efficacy assessments: The primary endpoint will be the 1-year HBe-Ag seroconversion rate with or without prednisolone priming. Data analysis: A summary table will be presented as frequency tables for categorical variables as number, and percentage, whereas descriptive tables for continuous variables as number, mean SD and median (minimum, maximum). All statistical assessments will be two-sided and evaluated at significance level of 0. 05. Continuous variables will be analyzed using t-test, or ANOVA, and categorical variables will be analyzed using chi-square or Fisher's exact test. A non-parametric method, Wilcoxon rank-sum or sign-rank tests will be conducted for continuous, and categorical variables if data is far from normal distribution.

Biomarkers of Prednisolone Treatment (P05888) [Completed]
Primary objective:

- To identify a biomarker or biomarker-set for the adverse metabolic effects of various

doses of prednisolone treatment. Secondary objectives:

- To describe the PK of prednisolone and PD of a series of biomarkers.

- To identify biomarkers that reflect side effects of prednisolone.

- To elucidate part of the mechanisms by which prednisolone induces metabolic changes.

Dexamethasone Versus Depo Medrol in Lumbar Epidurals [Terminated]
Comparison of Dexamethasone versus Depo Medrol when used in lumbar epidural injections will be conducted on subjects that have not had previous injections or have not had an injection in the last 12 months. Subjects must be receiving one level injection and not had prior surgery at that level.

Preoperative Methylprednisolone in Endovascular Aortic Repair [Completed]

more trials >>

Reports of Suspected Depo-Medrol (Methylprednisolone) Side Effects

Incorrect Route of Drug Administration (11)Drug Ineffective (9)Headache (7)Wrong Drug Administered (6)Rotator Cuff Syndrome (6)Depression (6)Pain (5)Psoas Abscess (5)Medication Error (5)Tendonitis (5)more >>


Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015